OF
OFK.F Orion Oyj
- Market cap
- EUR 14.4B
- P/E
- 22.0x
- P/B
- 10.26x
- ROE
- 38.0%
- Dividend yield
- 1.60%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OFK.F undervalued?
Graham numberThe Graham number of Orion Oyj cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Orion Oyj fundamental analysis
No fundamental analysis for Orion Oyj yet.
Orion Oyj stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Orion Oyj
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart fa…
Full company profileOrion Oyj financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Orion Oyj annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.07B | 1.08B | 977M | 1.05B | 1.08B | 1.04B | 1.34B | 1.19B | 1.54B | 1.89B | 1.98B |
| Gross Profit | 652M | 644M | 590M | 633M | 651M | 594M | 849M | 658M | 946M | 1.21B | 1.28B |
| Operating Income | 292M | 293M | 251M | 252M | 277M | 238M | 436M | 265M | 415M | 629M | 668M |
| EBITDA | - | 333M | 295M | 309M | 336M | 289M | 489M | 329M | 514M | 693M | 668M |
| Net Income | 249M | 226M | 330M | 200M | 220M | 194M | 350M | 217M | 330M | 500M | 531M |
| EPS | - | 1.61 | 2.35 | 1.43 | 1.57 | 1.38 | 2.49 | 1.54 | 2.35 | 3.56 | 3.78 |
| Balance Sheet | |||||||||||
| Total Assets | 1.06B | 1.06B | 1.15B | 1.04B | 1.12B | 1.11B | 1.50B | 1.44B | 1.63B | 2.01B | 2.03B |
| Total Liabilities | 422M | 376M | 374M | 256M | 384M | 366M | 596M | 549M | 624M | 725M | 636M |
| Shareholders' Equity | 641M | 680M | 773M | 779M | 731M | 748M | 908M | 890M | 1.01B | 1.28B | 1.40B |
| Cash & Short-term Investments | 201M | 164M | 249M | 114M | 294M | 217M | 333M | 107M | 206M | 161M | 144M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 249M | 228M | 231M | 271M | 299M | 216M | 434M | 119M | 293M | 317M | 543M |
| Capital Expenditure | 47.7M | 67.1M | 38.1M | 28.7M | 34.0M | 47.0M | 56.5M | 117M | 86.9M | 97.6M | 101M |
| Free Cash Flow | - | 152M | 164M | 235M | 258M | 131M | 361M | 2.20M | 207M | 219M | 441M |
| Ratios | |||||||||||
| ROE | 38.8% | 33.2% | 42.7% | 25.7% | 30.1% | 25.9% | 38.5% | 24.4% | 32.8% | 38.9% | 38.0% |
| ROA | 23.4% | 21.4% | 28.8% | 19.3% | 19.7% | 17.4% | 23.2% | 15.1% | 20.3% | 24.9% | 26.1% |
| Net Profit Margin | 23.2% | 20.8% | 33.8% | 19.1% | 20.4% | 18.6% | 26.1% | 18.2% | 21.4% | 26.5% | 26.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Orion Oyj dividends
- Dividend yield
- 1.60%
- Forward dividend
- 1.80 EUR
- Payout ratio
- 46.2%
- Ex-dividend date
- Oct 19, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 231M | 1.64 | 46.2% |
| 2024 | EUR 228M | 1.62 | 69.1% |
| 2023 | EUR 225M | 1.60 | 103.7% |
| 2022 | EUR 211M | 1.51 | 60.4% |
| 2021 | EUR 211M | 1.50 | 109.0% |
| 2020 | EUR 211M | 1.50 | 96.0% |
| 2019 | EUR 211M | 1.50 | 105.4% |
| 2018 | EUR 204M | 1.45 | 61.7% |
| 2017 | EUR 190M | 1.35 | 84.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Orion Oyj
- Insiders 2.63%
- Institutions 46.60%
- Public & others 50.77%
- Shares outstanding 109M
- Free float 123M
Orion Oyj company profile
- Company name
- Orion Oyj
- Ticker
- OFK.F
- ISIN
- FI0009014377
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,215
- Fiscal year end
- December
- Address
- Orionintie 1A, Espo, Finland, 02200
- Phone
- 358 10 4261
- Website
- orionpharma.com
About Orion Oyj
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
Orion Oyj management
10- Dr. Liisa Hurme Ph.D.President, CEO & Chairman of Executive Management Board · born 1967
- Mr. Rene Lindell M.Sc., Ph.D.CFO & Member of Group Executive Management Board · born 1976
- Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)Executive VP of Generics and Consumer Health & Member of the Exe. Mgmt. Board · born 1966
- Prof. Outi Vaarala M.D., Ph.D.Executive VP of Research & Development and Member of the Exe. Mgmt. Board · born 1962
- Mr. Juhani Kankaanpaa M.Sc.Executive VP of Global Operations & Member of Executive Management Board · born 1980
- Mr. Niclas Lindstedt EMBA, M.Sc.Executive VP of Animal Health & Member of the Exe. Mgmt. Board · born 1966
- Mr. Hao Pan M.Sc.Executive VP of the Branded Products & Member of the Exe. Mgmt. Board · born 1971
- Ms. Julia Irene MachareyExecutive VP of People & Culture & Member of Management Board · born 1977
- Mr. Mikko KemppainenGeneral Counsel, Secretary to the Board & Member of Executive Management Board · born 1972
- Mr. Berkeley VincentExecutive Vice President of Innovative Medicines & Member of Management Board · born 1977